FDA approves the first Humira biosimilar – PharmaTimes

US regulators have issued a green light for the first biosimilar of AbbVie’s biologic Humira, the world second best-selling drug. Amgen’s Amjevita has been cleared for all eligible indications of its reference product, including moderate-to-severe rheumatoid arthritis, moderate-to-severe polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, moderate-to-severe chronic plaque psoriasis, adult moderate-to-severe Crohn’s disease and moderate-to-severe ulcerative colitis.

Read The Full Source: FDA approves the first Humira biosimilar – PharmaTimes

Tags:
0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

HSAWARENESS.ORG | Fighting for Hidradenitis suppurativa (HS), a.k.a Acne Inversa Patient and Doctor Awareness ©2017 hidradenitissuppurativaawareness.org  All Rights Reserved. Your use of this website constitutes explicit agreement to our Terms of Use and Privacy Policies. This website does not provide medical advice, diagnosis or treatment.

Translate »

Log in with your credentials

Forgot your details?